Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

Item

http://www.wikidata.org/entity/Q41489984

Q41489984

about

Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis.The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.Current achievements and future perspectives of metronomic chemotherapy.Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.Therapeutic blockade of Foxp3 in experimental breast cancer models.Immunotherapeutic interventions of Triple Negative Breast Cancer.

P2860

Q26745462-F401E0F8-4FE3-44FB-97C9-61A373EA8C6B Q36309028-A6A3201F-0B0E-4588-88D6-412F84780C4C Q36562375-A14E4ABF-32CF-41D8-8C2C-A258DEBAB723 Q38788234-C2AFC1A1-4710-419E-987E-08AD823EFF9B Q47732726-2D2659D3-B5E7-417B-B083-24FDCD96794A Q48114047-90CE800E-8F45-46FC-9E00-3A7F652EE146 Q48325267-405BD972-635E-408D-ACAD-5B5C7F31E5F2 Q55257180-B7DD1952-9678-450F-9D55-D8BD6121714C

P2860

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

Item

http://www.wikidata.org/entity/Q41489984

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Prospective study of cyclophos ...... t cancers patients (aged <45).

@en

type

Item

label

Prospective study of cyclophos ...... t cancers patients (aged <45).

@en

prefLabel

Prospective study of cyclophos ...... t cancers patients (aged <45).

@en

P1476

Prospective study of cyclophos ...... t cancers patients (aged <45).

@en

P2093

G Song

http://www.w3.org/2001/XMLSchema#string

H Yang

http://www.w3.org/2001/XMLSchema#string

J Jia

http://www.w3.org/2001/XMLSchema#string

J Ren

http://www.w3.org/2001/XMLSchema#string

J Yu

http://www.w3.org/2001/XMLSchema#string

J Zhang

http://www.w3.org/2001/XMLSchema#string

L Che

http://www.w3.org/2001/XMLSchema#string

L Di

http://www.w3.org/2001/XMLSchema#string

N Jiang

http://www.w3.org/2001/XMLSchema#string

X Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.

Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

P2888

s12094-015-1339-2

P304

82-87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-015-1339-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Herbert Kim Lyerly

P577

2015-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281058052

http://www.w3.org/2001/XMLSchema#string

P698

26266766

http://www.w3.org/2001/XMLSchema#string

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

about

P2860

P2860

Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698